Evidence map›Paper›PMID 40457363›Full record

ArticleDiagnostic pathology2025

High-accuracy prediction of mutations in nine genes in lung adenocarcinoma via two-stage multi-instance learning on large-scale whole-slide images.

Lingyu Zhao, Na Zhao, Ruiqi Zhong, Yiru Niu, Ziyi Chang, Peng Su, Zhihui Wang, Lifang Cui, Bei Wang, Huang Chen and 5 more

Abstract read
In one paragraph

Article in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lingyu ZhaoDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Na ZhaoChongqing Zhijian Life Technology Co. LTD, Chongqing, 400039, China.
Ruiqi ZhongChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100006, China.
Yiru NiuDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Ziyi ChangDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Peng SuDepartment of Pathology, Ordos Central Hospital, Ordos, 017000, China.
Zhihui WangDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Lifang CuiDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Bei WangDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Huang ChenDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China.
Xiaowen WangChongqing Zhijian Life Technology Co. LTD, Chongqing, 400039, China.
Xiangbing KongChongqing Zhijian Life Technology Co. LTD, Chongqing, 400039, China.
Baolin DuChongqing Zhijian Life Technology Co. LTD, Chongqing, 400039, China.
Fei RenState Key Lab of Processors, Institute of Computing Technology, CAS, Beijing, 100190, China.
Dingrong ZhongDepartment of Pathology, China-Japan Friendship Hospital, Beijing, 100029, China. 748803069@qq.com.

Funding

2023 Science and Technology Projects of Qinghai Province, China (Basic Research Program) 2023-ZJ-732CAMS Innovation Fund for Medical Sciences (CIFMS) 2022-I2M-C&T-B-108CAMS Innovation Fund for Medical Sciences (CIFMS) 2023-I2M-C&T-B-120National Natural Science Foundation of China 82473138Science and Technology Innovation Key R&D Program of Chongqing CSTB2022TIAD-STX0008The National High Level Hospital Clinical Research Funding of China 2022-NHLHCRF-LX-01-0206
6 · The paper itself

Abstract

backgroundLung cancer is widely recognized as a prevalent malignant neoplasm. Traditional genetic testing methods face limitations such as high costs and lengthy procedures. The prediction of clinically relevant genetic mutations via histopathological images could facilitate the expedited identification of genetic mutations in clinical settings.

methodsWe collected 2,221 slides from 1999 patients diagnosed with lung adenocarcinoma. The data include whole-slide images data as well as information on gene mutations in EGFR, KRAS, ALK, HER2, and other rare genes (ROS1, RET, BRAF, PIK3CA, NRAS), and related clinical information. The self-supervised model DINO and the two-stage multi-instance network GAMIL were employed to accurately identify mutation statuses in 9 genes linked to tumorigenesis and cancer progression. The comparison of model performance involves the utilization of various foundation model (UNI), classification models (CLAM and Inception v3), external datasets (TCGA and other medical institutions), and comparative analysis with human pathologists.

resultsOur approach outperforms the CLAM and inception v3 model, achieving AUC values ranging from 0.825 to 0.987 for predicting gene mutations. The AUC value on the external test data set is 0.516-0.843. Furthermore, when comparing EGFR gene mutation prediction between pathologists and the GAMIL model, GAMIL exhibited a significantly higher AUC value of 0.810, exceeding the average AUC value of 0.508 achieved by pathologists.

conclusionThe GAMIL models exhibit outstanding performance in delineating tumor regions in lung adenocarcinoma and in forecasting gene mutations. The utilization of these models presents substantial potential for markedly improving molecular testing efficiency and opening novel pathways for personalized treatment.

trial registrationNot applicable.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsMutationDNA Mutational AnalysisFemaleHumansMaleMiddle AgedBiomarkers, TumorArtificial intelligenceGene mutationLung adenocarcinomaMultiple instance learningSelf-supervised

Identifiers

PMID40457363
PMCPMC12128265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.